DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Ademetionine is an investigational drug.
There have been 7 clinical trials for Ademetionine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Drug-Induced Liver Injury, Hepatitis B, and Liver Diseases, Alcoholic. The leading clinical trial sponsors are Beijing 302 Hospital, ClinIntel, and MSI Methylation Sciences, Inc.
There is one US patent protecting this investigational drug and nineteen international patents.
Recent Clinical Trials for Ademetionine
|Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial||Li Yang||Phase 4|
|36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI||Beijing 302 Hospital||Phase 1/Phase 2|
|Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI||Beijing 302 Hospital||Phase 1/Phase 2|
Top disease conditions for Ademetionine
Top clinical trial sponsors for Ademetionine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ademetionine||Start Trial||Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency||NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Kumamoto, JP)||Start Trial|
|Ademetionine||Start Trial||Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods||DexCom, Inc. (San Diego, CA)||Start Trial|
|Ademetionine||Start Trial||RNA preparations comprising purified modified RNA for reprogramming cells||THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA)||Start Trial|
|Ademetionine||Start Trial||Methanocarba derivatives of pseudoribose that inhibit adenosine kinase||Legacy Emanuel Hospital & Health Center (Portland, OR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|Ademetionine||Start Trial||Synthetic peptide amides and dimers thereof||Cara Therapeutics, Inc. (Stamford, CT)||Start Trial|
|Ademetionine||Start Trial||Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same||THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Stanford, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ademetionine||European Patent Office||EP2644694||2030-10-28||Start Trial|
|Ademetionine||World Intellectual Property Organization (WIPO)||WO2012056997||2030-10-28||Start Trial|
|Ademetionine||European Patent Office||EP3068302||2033-11-14||Start Trial|
|Ademetionine||World Intellectual Property Organization (WIPO)||WO2015073588||2033-11-14||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|